Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma

Blood Cancer Journal

Volumn 3, Issue 12, 2013, Pages

  Hiraoka, N ^a   Kikuchi, J ^a   Koyama, D ^a   Wada, T ^a   Mori, S ^b   Nakamura, Y ^b   Furukawa, Y ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H3K18; HISTONE H4; PERFOSFAMIDE; PROTEIN P53; ROMIDEPSIN; SIRTUIN 2; SIRTUIN 6; SIRTUIN 7; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER RESISTANCE; DOWN REGULATION; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYPERACETYLATION; LETTER; MANTLE CELL LYMPHOMA; NONHUMAN; OSMOTIC STRESS; UPREGULATION;

EID: 84892179612     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.66     Document Type: Letter

References (15)

1. Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ. Adenovirus small e1a alters global patterns of histone modification. Science 2008; 321: 1084-1085.
2. Eskandarian HA, Impens F, Nahori M-A, Soubigou G, Coppée J-Y, Cossart P et al. A role for SIRT2-dependent histone H3K18 deacetylation in bacterial infection. Science 2013; 341: 1238858.
3. Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 2012; 487: 114-118.
4. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-1266. (Pubitemid 40943093)
5. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: Results from RTOG 9704. J Clin Oncol 2010; 28: 1358-1365.
6. Leshchenko VV, Kuo P-Y, Shaknovich R, Yang DT, Gellen T, Petrich A et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010; 116: 1025-1034.
7. Vose JM. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2012; 87: 605-609.
8. Blackwell JS, Wilkinson ST, Mosammaparast N, Pemberton LF. Mutational analysis of H3 and H4 N termini reveals distinct roles in nuclear import. J Biol Chem 2007; 282: 20142-20150. (Pubitemid 47099983)
9. Qian M-X, Pang Y, Liu CH, Haratake K, Du B-Y, Ji D-Y et al. Acetylation-mediated proteasomal degradation of core histones during DNA repair and spermatogenesis. Cell 2013; 153: 1012-1024.
10. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010; 6: 238-243.
11. Summers AR, Fischer MA, Stengel KR, Zhao Y, Kaiser JF, Wells CE et al. Hdac3 is essential for DNA replication in hematopoietic progenitor cells. J Clin Invest 2013; 123: 3112-3123.
12. Xia Y, Wang J, Liu T-J, Yung WKA, Hunter T, Lu Z. c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. Mol Cell 2007; 25: 219-232. (Pubitemid 46109614)
13. Escaffit F, Vaute O, Chevillard-Briet M, Segui B, Takami Y, Nakayama T et al. Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Mol Cell Biol 2007; 27: 554-567. (Pubitemid 46080124)
14. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 2010; 24: 1760-1768.
15. Kikuchi J, Yamada S, Koyama D, Wada T, Nobuyoshi M, Izumi T et al. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. J Biol Chem 2013; 288: 25593-25602.